All News
Early GI Involvement Predictive of Scleroderma Outcomes
Rheumatology has published a cohort study showing that earlyGI symptoms and overall symptom burden predict both GI progression and mortality in Systemic Sclerosis (SSc).
Read Article
Hydroxychloroquine: 5 mg/kg/day Is Only the Starting Point
Hydroxychloroquine (HCQ) is one of the most important drugs in rheumatology, especially for systemic lupus erythematosus (SLE). It reduces flares, organ damage, cardiovascular events, and pregnancy complications, and it improves survival.
Read Article
Immune-Mediated Inflammatory Diseases Following Uveitis
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
Read Article
Press release of early study of IMVT-1402 (human mAb targeting FcRn) Open-label Rx in 170 active, refractory RA showed ACR 20/50/70 of 73%/54%/36% at wk 16. Next, Responders will do a blinded withdrawl - blinded results to follow. https://t.co/Mzmb3PPvMF https://t.co/oZ99l9VJQU
Dr. John Cush RheumNow ( View Tweet)
NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/SlLO35JhvY
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s global faculty reporters help translate the data into clinical practice.
Featuring:
✨ Dr. Janet Pope (@Janetbirdope)
✨ Dr. Yuz Yusof (@Yuz6Yusof)
✨ Dr. Jiha Lee (@JihaRheum)
✨ Dr. Mrinalini Dey (@DrMiniDey)
✨ Dr. Aurelie Najm (@AurelieRheumo)
✨ Dr. Bella https://t.co/0Pm0uUwRNf
Dr. John Cush RheumNow ( View Tweet)
True or False: In a registry of SLE patients, RNP-positive patients showed lower disease activity and less prednisone use. If you think you know the answer, prove it in this week's RheumIQ quiz at https://t.co/DTabBEfjj9
Dr. John Cush RheumNow ( View Tweet)
Kissei Pharmaceuticals announced 20 deaths related to receiving avacopan (Tavneos), a vasculitis drug sold by the firm in Japan. Drug was released in June 2022, since its been given to ~8,500 pts. Avacopan safety is being reviewed by FDA with Amgen. https://t.co/ri0nROCL5U https://t.co/jbksrWMFwI
Dr. John Cush RheumNow ( View Tweet)
FDA has approved a dosing update for burosumab-twza (Crysvita, Kyowa Kirin) to allow for increased dose and frequency when needed in adults with X-linked hypophosphatemia (XLH). https://t.co/EPyp6tDsaf https://t.co/1HEaQRk9BR
Dr. John Cush RheumNow ( View Tweet)
Goofy study of the month! (pub in JAMA!) RCT 170 adults w/ chronic LBP + MRI disc herniation found that amoxicillin-clavulanate, 500 mg/125 mg bid x 3 mos did not improve pain at 3 or 12 mos (vs PBO). Whatha... https://t.co/njrw6itAP8 https://t.co/CW2ssNPxf1
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-17 was assoc w/ nonresponse to MTX. Yet, still not good response biomarkers. TNF-α & GM-CSF did not assoc w/ MTX outcomes https://t.co/YIQKop9LMH https://t.co/XxwcRsKwoM
Dr. John Cush RheumNow ( View Tweet)
Israel study 264,858 pregnancies- 1st trimester NSAID exposure had no risk of congenital malformations (MCM). 8% exposed vs unexposed: overall MCM 8.2% v 7%; aRR 0.99). MCMs not incr = MSK, CV, CNS, cleft palate, GI, GU, nonsignif MSM aRR from 0.77- 1.05 https://t.co/ytYhBFl44o https://t.co/1fq4D1KykM
Dr. John Cush RheumNow ( View Tweet)
ABA versus HCQ in Palindromic Rheumatism
Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. https://t.co/z0ptEYdhQj
Dr. John Cush RheumNow ( View Tweet)
APR: Fibromyalgia
Dr. Jack Cush reviews Fibromyalgia as part of the Advanced Practice Rheum video series.
https://t.co/jq6dSXy6SU https://t.co/bDGRhhY2D9
Links:
Dr. John Cush RheumNow ( View Tweet)
In this week's RheumIQ quiz: An RA patient has a current or new cancer. With which cancer should you avoid/stop the use of a TNF inhibitor? See if you got it right at https://t.co/DTabBEfjj9 https://t.co/tVYUEjAPy3
Dr. John Cush RheumNow ( View Tweet)
Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zGjb3uSkjP https://t.co/3bdGAvKXAm
Dr. John Cush RheumNow ( View Tweet)
Medical Economics reports only 18% MDs practiced in MD-owned settings, a new low. By Jan '26 hospitals or corporate employment rose to 550,494 & independent MDs fell to 120,900 https://t.co/l0tt3yO9kt https://t.co/pkgmHFPjE1
Dr. John Cush RheumNow ( View Tweet)
Depression screening (PHQ-8) equally accurate in pts w/ & w/o chronic pain. Depression screening is not biased by overlapping symptoms in depression and chronic pain. https://t.co/UWf97NDPAK https://t.co/7dvt35RT9E
Links:
Dr. John Cush RheumNow ( View Tweet)
Infectious Rheumatology (5.15.2026)
Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.
https://t.co/MzqDykG78w https://t.co/z7BsADXo4x
Dr. John Cush RheumNow ( View Tweet)
Update on Multicentric Reticulohistiocytosis
Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry, it's a rare non-Langerhans cell histiocytosis condition characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and it has only been https://t.co/koXOwktDgA
Dr. John Cush RheumNow ( View Tweet)
